“Not only has the CF-1 allowed us to move our science forward from a technical point-of-view, it was also a necessity from a scientific viewpoint. Our poliovirus VLPs are temperature sensitive, consequently if these VLPs are exposed to temperatures above 40°C, they undergo a conformational shift, increasing the size of the particles. This increase leads to these particles no longer being able to induce a long-term protective immunological response. Therefore, the CF-1’s ability to cool samples during the cell disruption process meant that we were able to maintain the correct conformation of our VLPs, allowing us to test these VLPs in animal models. The success of these trials has led to these VLPs being transferred to industry for Phase I clinical trials”
Lee Sherry – Leeds University
Effective Purification of virus like particles (VLP) towards vaccine manufacture.
